Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MLL rearrangement
i
Other names:
HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MLL rearrangement
Acute Myelogenous Leukemia
MLL rearrangement
Acute Myelogenous Leukemia
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
palbociclib
Sensitive: C2 – Inclusion Criteria
palbociclib
Sensitive
:
C2
MLL rearrangement
Acute Myelogenous Leukemia
MLL rearrangement
Acute Myelogenous Leukemia
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
MLL rearrangement
Acute Myelogenous Leukemia
MLL rearrangement
Acute Myelogenous Leukemia
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
venetoclax
Sensitive: C2 – Inclusion Criteria
venetoclax
Sensitive
:
C2
MLL rearrangement
Acute Myelogenous Leukemia
MLL rearrangement
Acute Myelogenous Leukemia
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
MLL rearrangement
Acute Lymphocytic Leukemia
MLL rearrangement
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
blinatumomab + inotuzumab ozogamicin
Resistant: C3 – Early Trials
blinatumomab + inotuzumab ozogamicin
Resistant
:
C3
MLL rearrangement
Acute Lymphocytic Leukemia
MLL rearrangement
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
inotuzumab ozogamicin
Resistant: C3 – Early Trials
inotuzumab ozogamicin
Resistant
:
C3
MLL rearrangement
B Acute Lymphoblastic Leukemia
MLL rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Resistant: C3 – Early Trials
blinatumomab
Resistant
:
C3
blinatumomab
Resistant: C3 – Early Trials
blinatumomab
Resistant
:
C3
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MLL rearrangement
B Acute Lymphoblastic Leukemia
MLL rearrangement
B Acute Lymphoblastic Leukemia
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
MLL rearrangement
Leukemia
MLL rearrangement
Leukemia
JQ-1
Sensitive: D – Preclinical
JQ-1
Sensitive
:
D
JQ-1
Sensitive: D – Preclinical
JQ-1
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login